ABOS Earnings

ABOS reported its FY2025Q3 earnings on 2025-11-12, showcasing a revenue of 0.00 against an estimate of , resulting in a 0% surprise. The EPS was -0.44, surpassing the expected -0.63 by 30.16%. The stock experienced a -1.02% price change on the earnings day and a -19.8% change over the next five days, reflecting market reactions to the results.

Following ABOS's FY2025Q3 earnings announcement on 2025-11-12, the stock price moved by -1.02% on the day of the release. Over the subsequent five days, it saw a -19.8% change. Historically, ABOS's stock price tends to shift by an average of 1.63% in the 10 days leading up to earnings and -2.67% in the 10 days following, providing insight into potential market.

For , analysts estimate ABOS's annual revenue to reach undefined, while the EPS is projected at -0.43. These estimates reflect recent revisions, with revenue estimates revised upward by 88.57% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between ABOS's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for were revised upward by 88.57%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, ABOS's stock price typically moves by 1.63% in the 10 days before its earnings and -2.67% in the 10 days after. For the upcoming earnings, analysts expect an EPS of -0.43 and revenue of undefined.

The company's financial health shows a net loss and a reliance on existing cash reserves, which is concerning. However, there is optimism in their strategic collaboration with JCR and ongoing trials, which could potentially lead to positive outcomes. The Q&A reveals cautious optimism and strategic planning, but also highlights uncertainties in clinical trial outcomes and financial sustainability. The lack of guidance and potential financial risks balance out the positive aspects, resulting in a neutral sentiment.